论文部分内容阅读
目的探讨唑来磷酸联合卡培他滨治疗乳腺癌多发骨转移的效果及安全性。方法将48例乳腺癌骨转移患者随机分为唑来磷酸联合卡培他滨组(治疗组)及单用唑来磷酸组(对照组),分别对两组进行镇痛效果、生存质量改善评价、骨转移灶治疗效果评价及观察不良反应。结果两组患者治疗后骨痛的镇痛效果评价、患者生存质量改善评价,差异均无统计学意义(P>0.05);两组骨转移灶治疗效果评价,差异有统计学意义(P<0.05);两组患者的乏力、发热、恶心、呕吐、腹泻发生率比较,差异均无统计学意义(P>0.05)。结论唑来磷酸联合卡培他滨对乳腺癌骨多发转移较单用唑来磷酸有较好的治疗效果。
Objective To investigate the efficacy and safety of zoledronic acid combined with capecitabine in the treatment of multiple bone metastases of breast cancer. Methods Forty eight patients with bone metastasis of breast cancer were randomly divided into zoledronic acid plus capecitabine group (treatment group) and zoledronic acid alone group (control group). The analgesic effect and quality of life improvement Evaluation of the therapeutic effect of bone metastases and observation of adverse reactions. Results The analgesic effect of bone pain and the evaluation of quality of life in both groups were not significantly different after treatment (P> 0.05). The therapeutic effect of bone metastases in both groups was statistically significant (P <0.05 There was no significant difference between the two groups in the incidence of fatigue, fever, nausea, vomiting and diarrhea (P> 0.05). Conclusion Zoledronic acid combined with capecitabine has better therapeutic effect on multiple bone metastases of breast cancer than zoledronic acid alone.